首页> 外文期刊>Translational psychiatry. >DLPFC transcriptome defines two molecular subtypes of schizophrenia
【24h】

DLPFC transcriptome defines two molecular subtypes of schizophrenia

机译:DLPFC转录组定义了精神分裂症的两种分子亚型

获取原文
           

摘要

Little is known about the molecular pathogenesis of schizophrenia, possibly because of unrecognized heterogeneity in diagnosed patient populations. We analyzed gene expression data collected from the dorsolateral prefrontal cortex (DLPFC) of post-mortem frozen brains of 189 adult diagnosed schizophrenics and 206 matched controls. Transcripts from 633 genes are differentially expressed in the DLPFC of schizophrenics as compared to controls at Bonferroni-corrected significance levels. Seventeen of those genes are differentially expressed at very high significance levels (10sup-8/sup after Bonferroni correction). The findings were closely replicated in a dataset from an entirely unrelated source. The statistical significance of this differential gene expression is being driven by about half of the schizophrenic DLPFC samples, and importantly, it is the same half of the samples that is driving the significance for almost all of the differentially expressed transcripts. Weighted gene co-expression network analysis (WGCNA) of the schizophrenic subjects, based on the transcripts differentially expressed in the schizophrenics as compared to controls, divides them into two groups. "Type 1" schizophrenics have a DLPFC transcriptome similar to that of controls with only four differentially expressed genes identified. "Type 2" schizophrenics have a DLPFC transcriptome dramatically different from that of controls, with 3529 expression array probes to 3092 genes detecting transcripts that are differentially expressed at very high significance levels. These findings were re-tested and replicated in a separate independent cohort, using the RNAseq data from the DLPFC of an independent set of schizophrenics and control subjects. We suggest the hypothesis that these striking differences in DLPFC transcriptomes, identified and replicated in two populations, imply a fundamental biologic difference between these two groups of diagnosed schizophrenics, and we propose specific paths for further testing and expanding the hypothesis.
机译:关于精神分裂症的分子发病机理知之甚少,可能是由于在诊断出的患者人群中无法识别的异质性。我们分析了从189例成人诊断为精神分裂症患者和206例匹配对照的死后冷冻大脑的背外侧前额叶皮层(DLPFC)收集的基因表达数据。与Bonferroni校正显着性水平的对照组相比,精神分裂症的DLPFC中来自633个基因的转录本差异表达。这些基因中的十七个以非常高的显着性水平差异表达(在Bonferroni校正后,<10 -8 )。从完全不相关的来源将发现紧密复制到数据集中。大约一半的精神分裂症DLPFC样本驱动着这种差异基因表达的统计意义,重要的是,正是这一半的样本驱动了几乎所有差异表达的转录本的重要性。精神分裂症患者的加权基因共表达网络分析(WGCNA)基于与对照相比在精神分裂症患者中差异表达的转录本,将其分为两组。 “ 1型”精神分裂症患者具有与对照相似的DLPFC转录组,仅鉴定了四个差异表达的基因。 “ 2型”精神分裂症患者的DLPFC转录组与对照显着不同,针对3 092个基因的3529个表达阵列探针检测到以非常高的显着性水平差异表达的转录本。使用来自一组独立的精神分裂症患者和对照组的DLPFC的RNAseq数据,对这些发现进行了重新测试并在一个单独的独立队列中进行了复制。我们提出这样的假设,即在两个种群中识别并复制的DLPFC转录组的这些显着差异,意味着这两组已诊断的精神分裂症患者之间存在根本的生物学差异,我们提出了进一步检验和扩展该假设的具体途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号